Different medical institutions have selected different imported and domestic brand instruments: 38 domestic and 58 imported.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Biodesix Makes the Case for VeriStrat Through New Study Biodesix通过新的研究证明了VeriStrat的可行性 The Biodesix VeriStrat test received an extra dose of validation last week through a 1,048-patient study published in the Oncol

Ortho Clinical Diagnostics, a global leader in diagnostic platforms and technologies, recently announced that its new digital chemistry system known as the VITROS XT 7600 has received the CE mark ahead of its launch overseas. The new technol

Bacterial or viral infection, that is the question. Haifa-Israel based MeMed Diagnostics is developing a point-of-care platform and immune-based test that will one day be able to provide answers. Such a test could help with the overuse and u

Nebula Genomics has raised $4.3 million in seed financing from venture capital firms and has also partnered with Veritas Genetics, the company said recently. Nebula, which was founded last year by Harvard University researchers including Ge

Nebula Genomics has raised $4.3 million in seed financing from venture capital firms and has also partnered with Veritas Genetics, the company said recently. Nebula, which was founded last year by Harvard University researchers including Ge

Illumina said recently that it has received regulatory clearance for its MiSeqDx system from the China National Drug Administration, enabling it to sell the system in China for diagnostic testing. The clearance of the MiSeqDx in China is a

In 2012, genetic testing company 23andMe announced the opening of its Application Programming Interface (API), which wasintended to empower developers to build a wide range of new applications and tools for the 23andMe community.Six years la

Roche said recently that the US Food and Drug Administration has approved its Cobas EGFR Mutation Test v2 as a companion diagnostic test with AstraZenecas cancer drug Iressa (gefitinib) for first-line treatment of patients with non-small ce

Bruker said recently it has signed a definitive agreement to acquire a majority interest in infectious disease molecular diagnostics firm Hain Lifescience.According to Bruker, Nehren, Germany-based Hain will add capabilities in tuberculosis

Bio-Rad Laboratories reported after the close of the market recentlythat its second quarter revenues increased 14 percent year over year, driven by growth in both its Life Science and Clinical Diagnostics businesses. For the three months end